Kyle Wood, MD, Associate Professor of Urology, University of Alabama ​at Birmingham, gives an overview of enteric hyperoxaluria. 

Dr. Wood explains that excessive absorption of dietary oxalate characterizes enteric hyperoxaluria. Roux-en-Y gastric bypass surgery or gastrointestinal disorder often causes it. Primary hyperoxaluria and enteric hyperoxaluria differ as patients with enteric hyperoxaluria absorb oxalate, leading to kidney stones, excruciating pain, and renal damage. There is currently no FDA-approved treatment for enteric hyperoxaluria, but management may include increased fluid intake, calcium supplements, and dietary restrictions. SYNB8802, an orally administered drug candidate under investigation, showed positive results in a phase 1b study for treating enteric hyperoxaluria.

To learn more about enteric hyperoxaluria and other rare metabolic disorders, visit